Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.-., Lainchbury, M., Brown, N., Walton, M.I., Eve, P.D., Boxall, K.J., et al. (2016). Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J med chem, Vol.59 (11), pp. 5221-5237.  show abstract

Rankin, S.S., Caldwell, J.J., Cronin, N.B., van Montfort, R.L. & Collins, I. (2016). Synthesis of a Ribose-Incorporating Medium Ring Scaffold via a Challenging Ring-Closing Metathesis Reaction. European j org chem, Vol.2016 (26), pp. 4496-4507.  show abstract

Walton, M.I., Eve, P.D., Hayes, A., Henley, A.T., Valenti, M.R., Brandon, A.K., Box, G., Boxall, K.J., Tall, M., Swales, K., et al. (2016). The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. Oncotarget, Vol.7 (3).

Sadok, A., McCarthy, A., Caldwell, J., Collins, I., Garrett, M.D., Yeo, M., Hooper, S., Sahai, E., Kuemper, S., Mardakheh, F.K., et al. (2015). Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis. Cancer research, Vol.75 (11), pp. 2272-2284.

Joshi, A., Newbatt, Y., McAndrew, P.C., Stubbs, M., Burke, R., Richards, M.W., Bhatia, C., Caldwell, J.J., McHardy, T., Collins, I., et al. (2015). Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. Oncotarget, Vol.6 (15).

Lainchbury, M., Matthews, T.P., McHardy, T., Boxall, K.J., Walton, M.I., Eve, P.D., Hayes, A., Valenti, M.R., de Haven Brandon, A.K., Box, G., et al. (2012). Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J med chem, Vol.55 (22), pp. 10229-10240.  show abstract

Ali, M.M., Bagratuni, T., Davenport, E.L., Nowak, P.R., Silva-Santisteban, M.C., Hardcastle, A., McAndrews, C., Rowlands, M.G., Morgan, G.J., Aherne, W., et al. (2011). Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. Embo j, Vol.30 (5), pp. 894-905.  show abstract

Reader, J.C., Matthews, T.P., Klair, S., Cheung, K.-., Scanlon, J., Proisy, N., Addison, G., Ellard, J., Piton, N., Taylor, S., et al. (2011). Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J med chem, Vol.54 (24), pp. 8328-8342.  show abstract

Caldwell, J.J., Welsh, E.J., Matijssen, C., Anderson, V.E., Antoni, L., Boxall, K., Urban, F., Hayes, A., Raynaud, F.I., Rigoreau, L.J., et al. (2011). Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J med chem, Vol.54 (2), pp. 580-590.  show abstract

McHardy, T., Caldwell, J.J., Cheung, K.M., Hunter, L.J., Taylor, K., Rowlands, M., Ruddle, R., Henley, A., de Haven Brandon, A., Valenti, M., et al. (2010). Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J med chem, Vol.53 (5), pp. 2239-2249.  show abstract

Workman, P. & Collins, I. (2010). Probing the probes: fitness factors for small molecule tools. Chem biol, Vol.17 (6), pp. 561-577.  show abstract

Smyth, L.A. & Collins, I. (2009). Measuring and interpreting the selectivity of protein kinase inhibitors. J chem biol, Vol.2 (3), pp. 131-151.  show abstract

Keown, L.E., Collins, I., Cooper, L.C., Harrison, T., Madin, A., Mistry, J., Reilly, M., Shaimi, M., Welch, C.J., Clarke, E.E., et al. (2009). Novel orally bioavailable gamma-secretase inhibitors with excellent in vivo activity. J med chem, Vol.52 (11), pp. 3441-3444.  show abstract

Matthews, T.P., Klair, S., Burns, S., Boxall, K., Cherry, M., Fisher, M., Westwood, I.M., Walton, M.I., McHardy, T., Cheung, K.M., et al. (2009). Identification of inhibitors of checkpoint kinase 1 through template screening. J med chem, Vol.52 (15), pp. 4810-4819.  show abstract

Caldwell, J.J., Davies, T.G., Donald, A., McHardy, T., Rowlands, M.G., Aherne, G.W., Hunter, L.K., Taylor, K., Ruddle, R., Raynaud, F.I., et al. (2008). Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J med chem, Vol.51 (7), pp. 2147-2157.  show abstract

Brough, P.A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J.E., Cheung, K.M., Collins, I., Davies, N.G., Drysdale, M.J., et al. (2008). 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J med chem, Vol.51 (2), pp. 196-218.  show abstract

Donald, A., McHardy, T., Rowlands, M.G., Hunter, L.J., Davies, T.G., Berdini, V., Boyle, R.G., Aherne, G.W., Garrett, M.D. & Collins, I., et al. (2007). Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J med chem, Vol.50 (10), pp. 2289-2292.  show abstract

Collins, I. & Workman, P. (2006). New approaches to molecular cancer therapeutics. Nat chem biol, Vol.2 (12), pp. 689-700.  show abstract

Collins, I., Caldwell, J., Fonseca, T., Donald, A., Bavetsias, V., Hunter, L.J., Garrett, M.D., Rowlands, M.G., Aherne, G.W., Davies, T.G., et al. (2006). Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg med chem, Vol.14 (4), pp. 1255-1273.  show abstract

Collins, I., Moyes, C., Davey, W.B., Rowley, M., Bromidge, F.A., Quirk, K., Atack, J.R., McKernan, R.M., Thompson, S.A., Wafford, K., et al. (2002). 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. J med chem, Vol.45 (9), pp. 1887-1900.  show abstract